Bonadonna, G., Valagussa, P., Rossi, A., et al . (1985). Ten year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res. and Treat. 5 : 95-115.
2.
Breast Cancer Trials Committee, Scottish Cancer Trials Office (Mrc), Edinburgh. (1987). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii, 171-175.
3.
Early Breast Cancer Trialists Collaborative Group. (1988). Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N. Engl. J. Med. 319: 1681-1692.
4.
Fisher, B., Constantino, J., Redmond, C., et al . (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumours. N. Engl. J. Med. 320: 479-484.
5.
Nissen-Meyer, R., Hoot, H., Kellgren, K., Mansson, B., Norin, T. (1985). Short perioperative versus long-term adjuvant chemotherapy. Recent Results Cancer Res . 98: 91-98.
6.
Nolvadex Adjuvant Trial Organisation. (1988 ). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer57:, 608-611.
7.
O'Reilly, S.M., Camplejohn, R.S., Barnes, D.M., Millis, R.R., Rubens, R.D., Richards, M.A. (1990). Node Negative Breast Cancer: Prognostic subgroupings defined by tumour size and flow cytometry. J. Clin. Oncol . 8, 2040-2046.
8.
O'Reilly, S.M. AND Richards, M.A. et al. (1990). Adjuvant CMF in patients with axillary node positive breast cancer - An update of the Guy's/Manchester trial. J. Clin. Oncol. 8, 2032-2039.
